209 related articles for article (PubMed ID: 36932129)
41. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
[TBL] [Abstract][Full Text] [Related]
42. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization.
Kakar S; Chen X; Ho C; Burgart LJ; Sahai V; Dachrut S; Yabes A; Jain D; Ferrell LD
Mod Pathol; 2009 Jan; 22(1):134-41. PubMed ID: 18997738
[TBL] [Abstract][Full Text] [Related]
43. Fibrolamellar carcinoma of the liver--a case report from Japan and a review of the literature.
Kohno H; Nagasue N; Taniura H; Nakamura T; Nagaoka S
HPB Surg; 1988 Sep; 1(1):77-80. PubMed ID: 2856433
[TBL] [Abstract][Full Text] [Related]
44. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract][Full Text] [Related]
45. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report.
Okano A; Hajiro K; Takakuwa H; Kobashi Y
Am J Gastroenterol; 1998 Jul; 93(7):1144-5. PubMed ID: 9672347
[TBL] [Abstract][Full Text] [Related]
46. Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas.
Vivekanandan P; Daniel H; Yeh MM; Torbenson M
Mod Pathol; 2010 Jun; 23(6):790-8. PubMed ID: 20228784
[TBL] [Abstract][Full Text] [Related]
47. Resection of a fibrolamellar carcinoma of the liver originating in the caudate lobe.
Machado MC; Herman P; Bacchella T; Pugliese V; Pinotti HW
Hepatogastroenterology; 1995; 42(6):993-5. PubMed ID: 8847058
[TBL] [Abstract][Full Text] [Related]
48. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
49. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
50. Fibrolamellar carcinoma: Challenging the challenge.
Lamarca A; Frizziero M; Fulton A; McNamara MG; Filobbos R; Hubner RA; Wardell S; Valle JW
Eur J Cancer; 2020 Sep; 137():144-147. PubMed ID: 32768872
[TBL] [Abstract][Full Text] [Related]
51. CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients.
Do RK; McErlean A; Ang CS; DeMatteo RP; Abou-Alfa GK
Br J Radiol; 2014 Aug; 87(1040):20140024. PubMed ID: 24896196
[TBL] [Abstract][Full Text] [Related]
52. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases.
Imkie M; Myers SA; Li Y; Fan F; Bennett TL; Forster J; Tawfik O
J Reprod Med; 2005 Aug; 50(8):633-7. PubMed ID: 16220774
[TBL] [Abstract][Full Text] [Related]
53. Fibrolamellar hepatocellular carcinoma in an infant and literature review.
Cruz O; Laguna A; Vancells M; Krauel L; Medina M; Mora J
J Pediatr Hematol Oncol; 2008 Dec; 30(12):968-71. PubMed ID: 19131794
[TBL] [Abstract][Full Text] [Related]
54. Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.
Dinh TA; Sritharan R; Smith FD; Francisco AB; Ma RK; Bunaciu RP; Kanke M; Danko CG; Massa AP; Scott JD; Sethupathy P
Cell Rep; 2020 Apr; 31(2):107509. PubMed ID: 32294439
[TBL] [Abstract][Full Text] [Related]
55. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.
Ward SC; Huang J; Tickoo SK; Thung SN; Ladanyi M; Klimstra DS
Mod Pathol; 2010 Sep; 23(9):1180-90. PubMed ID: 20495535
[TBL] [Abstract][Full Text] [Related]
56. Management of fibrolamellar hepatocellular carcinoma.
Chaudhari VA; Khobragade K; Bhandare M; Shrikhande SV
Chin Clin Oncol; 2018 Oct; 7(5):51. PubMed ID: 30395718
[TBL] [Abstract][Full Text] [Related]
57. Fibrolamellar hepatocarcinoma: case report and review of the literature.
Bârsu M
Rom J Morphol Embryol; 1991; 37(3-4):161-6. PubMed ID: 1667604
[TBL] [Abstract][Full Text] [Related]
58. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
59. [Fibrolamellar carcinoma of the liver: hepatocellular carcinoma with favourable prognosis].
Denis J; Grippon P; Legendre C; Tubiana JM; Lévy VG
Gastroenterol Clin Biol; 1984 Dec; 8(12):920-4. PubMed ID: 6097494
[TBL] [Abstract][Full Text] [Related]
60. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
